KR20220145894A - 신규 항체 - Google Patents

신규 항체 Download PDF

Info

Publication number
KR20220145894A
KR20220145894A KR1020227033455A KR20227033455A KR20220145894A KR 20220145894 A KR20220145894 A KR 20220145894A KR 1020227033455 A KR1020227033455 A KR 1020227033455A KR 20227033455 A KR20227033455 A KR 20227033455A KR 20220145894 A KR20220145894 A KR 20220145894A
Authority
KR
South Korea
Prior art keywords
seq
antibody
fragment
sequence
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227033455A
Other languages
English (en)
Korean (ko)
Inventor
옥사나 폴리아코바
올리버 누스바우머
아드리안 헤이데이
피에르 반투루트
Original Assignee
감마델타 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 감마델타 테라퓨틱스 리미티드 filed Critical 감마델타 테라퓨틱스 리미티드
Publication of KR20220145894A publication Critical patent/KR20220145894A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020227033455A 2020-02-24 2021-02-24 신규 항체 Pending KR20220145894A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2002581.3A GB202002581D0 (en) 2020-02-24 2020-02-24 Novel antibodies
GB2002581.3 2020-02-24
PCT/GB2021/050459 WO2021171002A1 (en) 2020-02-24 2021-02-24 Novel antibodies

Publications (1)

Publication Number Publication Date
KR20220145894A true KR20220145894A (ko) 2022-10-31

Family

ID=70108379

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227033455A Pending KR20220145894A (ko) 2020-02-24 2021-02-24 신규 항체
KR1020227029501A Pending KR20220164473A (ko) 2020-02-24 2021-02-24 생체외 감마 델타 t 세포 집단

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227029501A Pending KR20220164473A (ko) 2020-02-24 2021-02-24 생체외 감마 델타 t 세포 집단

Country Status (17)

Country Link
US (2) US20230159638A1 (https=)
EP (3) EP4591882A3 (https=)
JP (2) JP2023516925A (https=)
KR (2) KR20220145894A (https=)
CN (2) CN115697401A (https=)
AU (2) AU2021228266A1 (https=)
BR (2) BR112022016894A2 (https=)
CA (2) CA3168973A1 (https=)
CL (1) CL2022002296A1 (https=)
CO (2) CO2022013542A2 (https=)
EC (1) ECSP22074030A (https=)
GB (1) GB202002581D0 (https=)
IL (2) IL295852A (https=)
MX (2) MX2022010383A (https=)
PE (1) PE20230438A1 (https=)
WO (2) WO2021171002A1 (https=)
ZA (1) ZA202209699B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
AU2022222299A1 (en) 2021-02-17 2023-09-07 F-Star Therapeutics Limited Multispecific anti-tcr delta variable 1 antibodies
CN119080924B (zh) * 2024-07-04 2025-02-25 上海交通大学医学院附属第九人民医院 一种单克隆免疫球蛋白及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081518A2 (en) * 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
AU2016274633B2 (en) * 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
EP3454870A4 (en) * 2016-05-12 2020-03-04 Adicet Bio Inc. METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
CA3145523A1 (en) * 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Therapeutic uses of anti-tcr delta variable 1 antibodies

Also Published As

Publication number Publication date
CO2022013542A2 (es) 2022-10-11
BR112022016671A2 (pt) 2022-11-16
CO2022013633A2 (es) 2023-02-16
JP2023514437A (ja) 2023-04-05
CN115697401A (zh) 2023-02-03
AU2021228266A1 (en) 2022-10-13
EP4591882A2 (en) 2025-07-30
EP4591882A3 (en) 2025-10-15
ECSP22074030A (es) 2022-10-31
CA3172340A1 (en) 2021-09-02
MX2022010239A (es) 2022-11-14
PE20230438A1 (es) 2023-03-08
MX2022010383A (es) 2022-09-05
IL295852A (en) 2022-10-01
WO2021171002A1 (en) 2021-09-02
EP4110387A1 (en) 2023-01-04
CN115461369A (zh) 2022-12-09
AU2021225390A1 (en) 2022-09-22
BR112022016894A2 (pt) 2023-04-04
WO2021171003A1 (en) 2021-09-02
CA3168973A1 (en) 2021-09-02
EP4110813A1 (en) 2023-01-04
CL2022002296A1 (es) 2023-03-31
US20230090901A1 (en) 2023-03-23
EP4110387B1 (en) 2025-05-21
JP2023516925A (ja) 2023-04-21
US20230159638A1 (en) 2023-05-25
IL295696A (en) 2022-10-01
GB202002581D0 (en) 2020-04-08
ZA202209699B (en) 2024-12-18
KR20220164473A (ko) 2022-12-13

Similar Documents

Publication Publication Date Title
TWI866043B (zh) 細胞毒性t淋巴球相關蛋白4(ctla-4)之新穎單株抗體
KR101516569B1 (ko) 사람 델타 유사 리간드 4에 대한 사람 항체
AU2016339832B2 (en) Antibody agents specific for human CD19 and uses thereof
KR101577843B1 (ko) 인간 ｏｘ４０ 수용체에 대한 결합 분자
CN114514245A (zh) 新颖的抗TCRδ可变1抗体
EP3470426A1 (en) Multispecific antibody
KR102439395B1 (ko) Ilt7 결합 분자 및 이의 사용 방법
PT2041177E (pt) Anticorpos com elevada afinidade para o receptor il-6 humano
KR20160090904A (ko) 치료 펩티드
KR20140033029A (ko) 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
CN113508139B (zh) 结合人lag-3的抗体、其制备方法和用途
KR20220145894A (ko) 신규 항체
TW202417496A (zh) 分離的抗原結合蛋白及其用途
JP2024535834A (ja) 抗ｃｄ４０抗体及びその用途
KR20210046725A (ko) 신규 암 면역요법 항체 조성물
HK40084452A (en) Novel antibodies
RU2846103C2 (ru) Антитела к CD20 собачьих
RU2804490C2 (ru) Новые композиции антител для иммунотерапии рака
HK40075692A (en) Novel anti-tcr delta variable 1 antibodies
HK40047112B (en) Novel cancer immunotherapy antibody compositions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220926

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application